Scientific deep-dive

GLP-1s and Cancer: The Randomized Answer

Randomized evidence finds little or no effect on obesity-related cancers: pancreatic somewhere between 9 fewer and 6 more per 10,000. The trials were not designed to look for cancer and had short follow-up.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·2 citations

We have already looked at what the observational cohorts say about cancer, and at how badly one of them behaved. Here is the randomized answer, from a systematic review in the Annals of Internal Medicine: GLP-1 drugs may have little or no effect on obesity-related cancers.[1] That is less reassuring than it sounds, for a reason the review itself gives.

What the trials showed

Pooled randomized evidence, at moderate certainty. Absolute ranges are per 10,000 people.
CancerOdds ratioAbsolute range
Pancreatic0.84 (95% CI 0.53–1.35)9 fewer to 6 more
Breast0.95 (95% CI 0.60–1.49)10 fewer to 12 more
Kidney1.12 (95% CI 0.78–1.60)5 fewer to 13 more

For colorectal, esophageal, liver, gallbladder, ovarian and endometrial cancer, and for multiple myeloma and meningioma, the review found, at low certainty, that the drugs may have little or no effect. For gastric cancer, the effect is very uncertain.[1]

Read the right-hand column rather than the odds ratios. “Nine fewer to six more pancreatic cancers per ten thousand people” tells you what is at stake: an effect small enough in either direction that it would be invisible to any individual. An odds ratio of 0.84 sounds like a 16% reduction, but its interval runs from 0.53 to 1.35, so the data are also compatible with an increase.

Why 'no effect' is not the same as 'safe'

The review states its central limitation directly: the included trials were not designed to evaluate cancer outcomes and had short follow-up.[1] That single sentence governs everything above, and it applies as much to an observational study in adults without diabetes whose median follow-up was two years.

Cancer takes years to appear, and these trials ran for one or two.

Cancer outcomes in these studies were recorded as adverse events, not hunted for as endpoints, in trials built around weight or cardiovascular disease. The same structural weakness produced the inflated dementia signal we covered in the EVOKE article, only here it cuts toward a null rather than a false positive.

What is reassuring, and what is not

  • Reassuring: results held consistent in sensitivity analyses restricted to low-risk-of-bias trials, and across semaglutide and tirzepatide specifically, and across subgroups by follow-up, population, dose and duration of action.[1] Consistency is the property that makes a null believable.
  • Reassuring: nothing points toward increased risk. The intervals sit around no effect rather than leaning toward harm.
  • Not reassuring: the follow-up is far too short for the question. Longer-term studies are needed, as the review says.
  • Not reassuring: the confidence intervals are wide enough to accommodate meaningful effects in either direction for several cancers.

How this sits with the cohort evidence

The cohorts suggested a small protective association: a hazard ratio of 0.87 for obesity-related cancers across 919,609 people.[2] The randomized trials suggest little or no effect. Those are not in conflict.

The cohorts have the years the trials lack and the confounding the trials do not. The trials have the randomization the cohorts do not and none of the time. Each is strong where the other is weak. Taken together they point to probably nothing dramatic in either direction, and nobody yet has the decade of data that would settle it.

The thyroid C-cell warning that appears on every label in this class is a separate question with its own evidence, covered in the thyroid cancer article. What the breast cancer row means alongside breast size, pain and mammograms is in GLP-1 drugs and breast changes.

Frequently Asked Questions

Randomized evidence does not suggest so. A systematic review found the drugs may have little or no effect on obesity-related cancers, with confidence intervals for pancreatic, breast and kidney cancer sitting around no effect at moderate certainty.
The randomized evidence does not support that either. Observational cohorts have suggested a small protective association, but the trials show little or no effect. Both can be true if the real effect is small.
Because the review says the included trials were not designed to evaluate cancer outcomes and had short follow-up. Cancer takes years to develop, and these trials ran one to two. An absence of signal in that window says more about the window than about the drug.
The pooled odds ratio was 0.84 with a confidence interval from 0.53 to 1.35, corresponding to somewhere between 9 fewer and 6 more cases per 10,000 people. That is a range spanning both directions and small enough to be invisible to any individual.
Longer-term studies, which the review explicitly calls for. Any firm claim in either direction today is running ahead of a follow-up period that does not yet exist.

References

  1. 1.Ko A, Chang YC, Bahar F, et al. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-Analysis Annals of Internal Medicine. 2026. PMID: 41359966.
  2. 2.Mao X, Zhang X, Henry L, et al. Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study Journal of the National Cancer Institute. 2025. PMID: 40632592.

Cancer Risk in People Without Diabetes

A study in obese adults without diabetes found 41% lower incidence of obesity-associated cancers. The median follow-up was two years, far too short to establish that a drug prevented anything.

6 min read

GLP-1s in People Being Treated for Cancer

Lower mortality and fewer hospitalizations than metformin, at a hazard ratio of 0.875. A second comparison against insulin produced a bigger number, and the bigger number is the less trustworthy one.

5 min read

GLP-1s and Cancer: What the Cohorts Actually Show

One study found breast cancer mortality 91% lower on GLP-1s than on insulin, and no difference at all against SGLT2 inhibitors. The comparison group produced the result. What is known, and how to read this kind of evidence.

7 min read

The Group That Lost Least Did Best

A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.

6 min read

Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show

GLP-1 drugs lower deaths from any cause by about 12% in people with heart disease, diabetes or kidney disease. No trial has tested them in healthy adults or measured lifespan. SELECT, FLOW, LEADER, dementia, cancer and muscle, in one place.

11 min read

Semax vs Selank: Two Russian Nasal Peptides, and Only One Is Now Covered

Semax is an ACTH fragment studied in stroke; Selank is a tuftsin analog studied in anxiety. Since October 28, 2026, HHS’s enforcement-discretion policy covers compounded intranasal Semax under 503A. Selank and Semax + Selank blends are not covered.

10 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

7.9

Luvo Health

Moving between compounded and brand without changing seller

7.1

Direct Meds

Compounded semaglutide at $249/month

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →